Looks like Tang at Deutche believes Zev is covered by the patent, and Toth at Prudential perhaps leaning that way as well. Of course, both have been CLTR bulls:
--10:37 am Coulter soars after receiving patent, IDEC tripped up
Coulter Pharmaceuticals (CLTR: news, msgs) is flying 5 3/4, or 26 percent higher, to 27 3/4. The company said that it has received a patent relating to radiolabeled antibodies for the treatment of Lymphoma. The patent covers its work on Bexxar, a radioimmunotherapy jointly developed with SmithKline Beecham (SBH: news, msgs). Analyst Kevin Tang at Deutsche Banc Alex. Brown believes it also covers the work IDEC Pharmaceuticals (IDPH: news, msgs) is doing on Zevalin, a competing product. Tang expects litigation involving the patent to start soon, and the outcome is uncertain. He reiterated his "strong buy" rating on Coulter's shares. SmithKline's stock is up 7/16 while IDEC's shares are slumping by 22 7/8, or 17 percent, to 110. Prudential Securities cut its rating on IDEC stock to "accumulate" from "strong buy."
www2.marketwatch.com
V1 - thanks for the fantastic update from H&Q, much appreciated... |
